Hemostemix (HMTXF, $0.04) was a top loser over the last three months, falling -2 to $0.04 per share. A.I.dvisor analyzed 895 stocks in the Biotechnology Industry for the 3-month period ending June 3, 2024, and found that of them (3) exhibited an Uptrend while of them (6) demonstrated a Downtrend.